WO2013186550A1 - Compound and method - Google Patents
Compound and method Download PDFInfo
- Publication number
- WO2013186550A1 WO2013186550A1 PCT/GB2013/051532 GB2013051532W WO2013186550A1 WO 2013186550 A1 WO2013186550 A1 WO 2013186550A1 GB 2013051532 W GB2013051532 W GB 2013051532W WO 2013186550 A1 WO2013186550 A1 WO 2013186550A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- formula
- compound
- catalyst
- mmol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 139
- 150000001875 compounds Chemical class 0.000 title claims abstract description 125
- -1 CO-R11 Chemical group 0.000 claims abstract description 98
- 230000008569 process Effects 0.000 claims abstract description 61
- 150000003180 prostaglandins Chemical class 0.000 claims abstract description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 31
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 20
- 125000006239 protecting group Chemical group 0.000 claims abstract description 20
- 125000005017 substituted alkenyl group Chemical group 0.000 claims abstract description 18
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 18
- 125000004426 substituted alkynyl group Chemical group 0.000 claims abstract description 16
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims abstract description 8
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims description 179
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 claims description 123
- 239000011541 reaction mixture Substances 0.000 claims description 123
- 239000003054 catalyst Substances 0.000 claims description 82
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 63
- 239000003426 co-catalyst Substances 0.000 claims description 56
- 230000002378 acidificating effect Effects 0.000 claims description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 54
- 230000015572 biosynthetic process Effects 0.000 claims description 51
- 150000003335 secondary amines Chemical class 0.000 claims description 50
- 239000002904 solvent Substances 0.000 claims description 49
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 239000003153 chemical reaction reagent Substances 0.000 claims description 27
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 25
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims description 21
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 239000012038 nucleophile Substances 0.000 claims description 20
- 229960001160 latanoprost Drugs 0.000 claims description 19
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 16
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 230000009467 reduction Effects 0.000 claims description 13
- 238000006845 Michael addition reaction Methods 0.000 claims description 12
- 229960002470 bimatoprost Drugs 0.000 claims description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 11
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims description 11
- 238000007248 oxidative elimination reaction Methods 0.000 claims description 11
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 150000002084 enol ethers Chemical class 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 7
- 238000007239 Wittig reaction Methods 0.000 claims description 7
- 229920001429 chelating resin Polymers 0.000 claims description 7
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 7
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 6
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 claims description 6
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical group 0.000 claims description 5
- 239000000376 reactant Substances 0.000 claims description 5
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 4
- STBUWXYTSVWZIS-UHFFFAOYSA-N morpholine;2,2,2-trifluoroacetic acid Chemical compound C1COCCN1.OC(=O)C(F)(F)F STBUWXYTSVWZIS-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-O morpholinium Chemical compound [H+].C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-O 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims description 4
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 238000006772 olefination reaction Methods 0.000 claims description 3
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 claims description 3
- NRTYMEPCRDJMPZ-UHFFFAOYSA-N pyridine;2,2,2-trifluoroacetic acid Chemical compound C1=CC=NC=C1.OC(=O)C(F)(F)F NRTYMEPCRDJMPZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960000948 quinine Drugs 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 2
- CWRWOECVPKDZIC-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]thiourea Chemical compound NC(=S)NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CWRWOECVPKDZIC-UHFFFAOYSA-N 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims description 2
- 150000004820 halides Chemical group 0.000 claims description 2
- RYUQZMGIWVNPPE-UHFFFAOYSA-N phenylmethanamine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC=C1 RYUQZMGIWVNPPE-UHFFFAOYSA-N 0.000 claims description 2
- HEZTYYBZXJQIRF-UHFFFAOYSA-N 2-pyridin-2-ylpyridine 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.c1ccc(nc1)-c1ccccn1 HEZTYYBZXJQIRF-UHFFFAOYSA-N 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 184
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 170
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 115
- 239000000243 solution Substances 0.000 description 115
- 239000000203 mixture Substances 0.000 description 100
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 92
- 229910052739 hydrogen Inorganic materials 0.000 description 91
- 235000019439 ethyl acetate Nutrition 0.000 description 84
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 76
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 74
- 239000007787 solid Substances 0.000 description 74
- 239000003921 oil Substances 0.000 description 71
- 235000019198 oils Nutrition 0.000 description 71
- 238000005481 NMR spectroscopy Methods 0.000 description 67
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 61
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 52
- 238000004440 column chromatography Methods 0.000 description 48
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 47
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 47
- 239000000126 substance Substances 0.000 description 38
- 238000005575 aldol reaction Methods 0.000 description 37
- 239000012074 organic phase Substances 0.000 description 37
- 230000002829 reductive effect Effects 0.000 description 37
- 229930182821 L-proline Natural products 0.000 description 35
- 239000000047 product Substances 0.000 description 35
- 238000003786 synthesis reaction Methods 0.000 description 34
- 239000000377 silicon dioxide Substances 0.000 description 32
- LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 description 30
- 239000000463 material Substances 0.000 description 29
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 29
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 28
- 239000000706 filtrate Substances 0.000 description 28
- 229920006395 saturated elastomer Polymers 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 27
- 150000001241 acetals Chemical class 0.000 description 24
- 229960002429 proline Drugs 0.000 description 24
- 238000000746 purification Methods 0.000 description 24
- 239000003208 petroleum Substances 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000013058 crude material Substances 0.000 description 21
- 238000011068 loading method Methods 0.000 description 21
- 238000003756 stirring Methods 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000654 additive Substances 0.000 description 18
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 18
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- GFISDBXSWQMOND-UHFFFAOYSA-N 2,5-dimethoxyoxolane Chemical compound COC1CCC(OC)O1 GFISDBXSWQMOND-UHFFFAOYSA-N 0.000 description 14
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 239000003377 acid catalyst Substances 0.000 description 12
- 150000001299 aldehydes Chemical class 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 238000004821 distillation Methods 0.000 description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 10
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 230000000996 additive effect Effects 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- OHBQPCCCRFSCAX-UHFFFAOYSA-N 1,4-Dimethoxybenzene Chemical compound COC1=CC=C(OC)C=C1 OHBQPCCCRFSCAX-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 8
- 230000018044 dehydration Effects 0.000 description 8
- 238000006297 dehydration reaction Methods 0.000 description 8
- 150000002596 lactones Chemical class 0.000 description 8
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 8
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 8
- 238000005949 ozonolysis reaction Methods 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- 238000010626 work up procedure Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 7
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229930192474 thiophene Natural products 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 0 C*(C)(CCC1)[C@@]1C(c1cc(*)cc(*)c1)(c1cc(*)cc(*)c1)OC Chemical compound C*(C)(CCC1)[C@@]1C(c1cc(*)cc(*)c1)(c1cc(*)cc(*)c1)OC 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 5
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 238000005356 chiral GC Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 238000005580 one pot reaction Methods 0.000 description 5
- 150000002924 oxiranes Chemical class 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 4
- 238000004566 IR spectroscopy Methods 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 229910004161 SiNa Inorganic materials 0.000 description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 150000000475 acetylene derivatives Chemical group 0.000 description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 4
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000002373 hemiacetals Chemical class 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 4
- RPUSRLKKXPQSGP-UHFFFAOYSA-N methyl 3-phenylpropanoate Chemical compound COC(=O)CCC1=CC=CC=C1 RPUSRLKKXPQSGP-UHFFFAOYSA-N 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 238000000526 short-path distillation Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- RGYWMXFWIZGWSF-LLVKDONJSA-N (3s)-5-phenylpent-1-yn-3-ol Chemical compound C#C[C@@H](O)CCC1=CC=CC=C1 RGYWMXFWIZGWSF-LLVKDONJSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003172 aldehyde group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000000538 analytical sample Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 3
- 239000004305 biphenyl Substances 0.000 description 3
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- GHXZPUGJZVBLGC-UHFFFAOYSA-N iodoethene Chemical compound IC=C GHXZPUGJZVBLGC-UHFFFAOYSA-N 0.000 description 3
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 3
- 238000006362 organocatalysis Methods 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 150000003147 proline derivatives Chemical class 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 3
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- HCKNRHBSGZMOOF-UHFFFAOYSA-N 1-methoxy-2-methylperoxyethane Chemical compound COCCOOC HCKNRHBSGZMOOF-UHFFFAOYSA-N 0.000 description 2
- ZLUQXZPDHMULKE-UHFFFAOYSA-N 2-oxo-3,3a,6,6a-tetrahydrocyclopenta[b]furan-5-carbaldehyde Chemical compound C1C(=O)OC2CC(C=O)=CC21 ZLUQXZPDHMULKE-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- YGCZTXZTJXYWCO-UHFFFAOYSA-N 3-phenylpropanal Chemical compound O=CCCC1=CC=CC=C1 YGCZTXZTJXYWCO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 2
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 2
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo[3.3.1]nonane Substances C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 2
- 239000007848 Bronsted acid Substances 0.000 description 2
- 125000006519 CCH3 Chemical group 0.000 description 2
- ZGRQPKYPJYNOKX-XUXIUFHCSA-N Cys-Cys-His-His Chemical compound C([C@H](NC(=O)[C@H](CS)NC(=O)[C@H](CS)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ZGRQPKYPJYNOKX-XUXIUFHCSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- SHCSFZHSNSGTOP-UHFFFAOYSA-N Methyl 4-pentenoate Chemical compound COC(=O)CCC=C SHCSFZHSNSGTOP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- VTJRERUMRARFOH-RFHHWMCGSA-N [(3ar,6as)-5-formyl-3,3a,6,6a-tetrahydro-2h-cyclopenta[b]furan-2-yl] benzoate Chemical compound C([C@@H]1C=C(C[C@@H]1O1)C=O)C1OC(=O)C1=CC=CC=C1 VTJRERUMRARFOH-RFHHWMCGSA-N 0.000 description 2
- AGIMDSXEQYKHQU-UHFFFAOYSA-N [5-(ethylamino)-5-oxopentyl]-triphenylphosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)NCC)C1=CC=CC=C1 AGIMDSXEQYKHQU-UHFFFAOYSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- KIGALSBMRYYLFJ-UHFFFAOYSA-N chloro-(2,3-dimethylbutan-2-yl)-dimethylsilane Chemical compound CC(C)C(C)(C)[Si](C)(C)Cl KIGALSBMRYYLFJ-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940090181 propyl acetate Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- QCIWZIYBBNEPKB-UHFFFAOYSA-N tert-butyl(dimethyl)silane Chemical compound C[SiH](C)C(C)(C)C QCIWZIYBBNEPKB-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 2
- PGOLTJPQCISRTO-UHFFFAOYSA-N vinyllithium Chemical compound [Li]C=C PGOLTJPQCISRTO-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- JVGAGAVQROERFI-JTQLQIEISA-N (2s)-2-(2-phenylethyl)oxirane Chemical compound C([C@@H]1OC1)CC1=CC=CC=C1 JVGAGAVQROERFI-JTQLQIEISA-N 0.000 description 1
- IAEZHIIUSKETBV-ZYOSVBKOSA-N (3ar,6as)-2-[2,3-dimethylbutan-2-yl(dimethyl)silyl]oxy-3,3a,6,6a-tetrahydro-2h-cyclopenta[b]furan-5-carbaldehyde Chemical compound C1=C(C=O)C[C@@H]2OC(O[Si](C)(C)C(C)(C)C(C)C)C[C@@H]21 IAEZHIIUSKETBV-ZYOSVBKOSA-N 0.000 description 1
- RELZRATWBLRFMD-JVIMKECRSA-N (3ar,6as)-2-methoxy-3,3a,6,6a-tetrahydro-2h-cyclopenta[b]furan-5-carbaldehyde Chemical compound C1=C(C=O)C[C@@H]2OC(OC)C[C@@H]21 RELZRATWBLRFMD-JVIMKECRSA-N 0.000 description 1
- TZSXQZZYXRKGCD-AWEZNQCLSA-N (3s)-5-phenyl-1-trimethylsilylpent-1-yn-3-ol Chemical compound C[Si](C)(C)C#C[C@@H](O)CCC1=CC=CC=C1 TZSXQZZYXRKGCD-AWEZNQCLSA-N 0.000 description 1
- VMUJXKHHANQVNB-LLVKDONJSA-N (3s)-5-phenylpent-1-en-3-ol Chemical compound C=C[C@@H](O)CCC1=CC=CC=C1 VMUJXKHHANQVNB-LLVKDONJSA-N 0.000 description 1
- VUGRNZHKYVHZSN-MRVPVSSYSA-N (3s)-oct-1-yn-3-ol Chemical compound CCCCC[C@H](O)C#C VUGRNZHKYVHZSN-MRVPVSSYSA-N 0.000 description 1
- DRWKZQHXBXCXEO-ONNUEXRDSA-N (4-benzamidophenyl) 7-[(1s,2r,3r)-3-hydroxy-2-(2-hydroxy-2-methylheptyl)sulfanyl-5-oxocyclopentyl]heptanoate Chemical compound CCCCCC(C)(O)CS[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC(C=C1)=CC=C1NC(=O)C1=CC=CC=C1 DRWKZQHXBXCXEO-ONNUEXRDSA-N 0.000 description 1
- MIOPJNTWMNEORI-XVKPBYJWSA-N (R)-camphorsulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)C[C@H]1C2(C)C MIOPJNTWMNEORI-XVKPBYJWSA-N 0.000 description 1
- PPTXVXKCQZKFBN-UHFFFAOYSA-N (S)-(-)-1,1'-Bi-2-naphthol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=C(O)C=CC2=C1 PPTXVXKCQZKFBN-UHFFFAOYSA-N 0.000 description 1
- OOAHNJDZICJECC-BHWPLRMJSA-N (z)-7-[(1r,2r,3r)-2-[(e,3r)-3-hydroxy-4,4-dimethyloct-1-enyl]-3-methyl-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](C)CC(=O)[C@@H]1C\C=C/CCCC(O)=O OOAHNJDZICJECC-BHWPLRMJSA-N 0.000 description 1
- AIOFTOLPMOTZKD-OPVFONCOSA-N (z)-7-[(1r,2r,3r,5r)-5-chloro-3-hydroxy-2-[(e,3r)-3-hydroxy-4,4-dimethyloct-1-enyl]cyclopentyl]hept-5-enoic acid Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H](Cl)[C@@H]1C\C=C/CCCC(O)=O AIOFTOLPMOTZKD-OPVFONCOSA-N 0.000 description 1
- UJFDLBWYYFZXDS-LEENOTDESA-N (z)-7-[(1s,2s,3s)-2-[(e,3s)-5-ethoxy-3-hydroxy-4,4-dimethylpent-1-enyl]-3-hydroxy-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCOCC(C)(C)[C@@H](O)\C=C\[C@@H]1[C@@H](O)CC(=O)[C@H]1C\C=C/CCCC(O)=O UJFDLBWYYFZXDS-LEENOTDESA-N 0.000 description 1
- RWXWQJYJWJNJNW-UHFFFAOYSA-N 1,3-bis[3,5-bis(trifluoromethyl)phenyl]thiourea Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(NC(=S)NC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=C1 RWXWQJYJWJNJNW-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 description 1
- XSGQFHNPNWBVPT-VFXMVCAWSA-N 15-methyl-15R-PGE2 Chemical compound CCCCC[C@@](C)(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XSGQFHNPNWBVPT-VFXMVCAWSA-N 0.000 description 1
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 description 1
- KXZIBRUIJDEWKY-UHFFFAOYSA-N 2,5-dimethoxyfuran Chemical compound COC1=CC=C(OC)O1 KXZIBRUIJDEWKY-UHFFFAOYSA-N 0.000 description 1
- JVGAGAVQROERFI-UHFFFAOYSA-N 2-(2-phenylethyl)oxirane Chemical compound C1OC1CCC1=CC=CC=C1 JVGAGAVQROERFI-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- VSEVUQXKWHTETG-UHFFFAOYSA-N 2h-cyclopenta[b]furan-2,5-diol Chemical compound OC1=CC2=CC(O)OC2=C1 VSEVUQXKWHTETG-UHFFFAOYSA-N 0.000 description 1
- ZLJOKYGJNOQXDP-OZUBPDBUSA-N 3-[(z)-[(3ar,4r,5r,6as)-4-[(e,3s)-3-cyclohexyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]methyl]benzoic acid Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@H]1C1)/C=C/[C@@H](O)C2CCCCC2)\C1=C/C1=CC=CC(C(O)=O)=C1 ZLJOKYGJNOQXDP-OZUBPDBUSA-N 0.000 description 1
- MTNPITXJKLMSKU-UHFFFAOYSA-N 3a,6,7,7a-tetrahydro-3h-1-benzofuran-2-one Chemical compound C1=CCCC2OC(=O)CC21 MTNPITXJKLMSKU-UHFFFAOYSA-N 0.000 description 1
- HLLSOEKIMZEGFV-UHFFFAOYSA-N 4-(dibutylsulfamoyl)benzoic acid Chemical compound CCCCN(CCCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 HLLSOEKIMZEGFV-UHFFFAOYSA-N 0.000 description 1
- JPVUWCPKMYXOKW-UHFFFAOYSA-N 4-phenylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1C1=CC=CC=C1 JPVUWCPKMYXOKW-UHFFFAOYSA-N 0.000 description 1
- WNXNUPJZWYOKMW-UHFFFAOYSA-N 5-bromopentanoic acid Chemical compound OC(=O)CCCCBr WNXNUPJZWYOKMW-UHFFFAOYSA-N 0.000 description 1
- TZSXQZZYXRKGCD-UHFFFAOYSA-N 5-phenyl-1-trimethylsilylpent-1-yn-3-ol Chemical compound C[Si](C)(C)C#CC(O)CCC1=CC=CC=C1 TZSXQZZYXRKGCD-UHFFFAOYSA-N 0.000 description 1
- VMUJXKHHANQVNB-UHFFFAOYSA-N 5-phenylpent-1-en-3-ol Chemical compound C=CC(O)CCC1=CC=CC=C1 VMUJXKHHANQVNB-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- WMLGLMGSFIXSGO-KTXJXPLISA-N 9-Deoxy-9-methylene-16,16-dimethyl -PGE2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=C)[C@@H]1C\C=C/CCCC(O)=O WMLGLMGSFIXSGO-KTXJXPLISA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- XUHYQIQIENDJER-BYPYZUCNSA-N C(C1)CN[C@@H]1c1nnn[nH]1 Chemical compound C(C1)CN[C@@H]1c1nnn[nH]1 XUHYQIQIENDJER-BYPYZUCNSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- QSPZLCRAOOMUNU-INIZCTEOSA-N CC(C)(C)[Si+](C)(C)O[C@@H](CCc1ccccc1)CCO Chemical compound CC(C)(C)[Si+](C)(C)O[C@@H](CCc1ccccc1)CCO QSPZLCRAOOMUNU-INIZCTEOSA-N 0.000 description 1
- CEPJXTONNYWYJX-YFKPBYRVSA-N CS(NC([C@H]1NCCC1)=O)(=O)=O Chemical compound CS(NC([C@H]1NCCC1)=O)(=O)=O CEPJXTONNYWYJX-YFKPBYRVSA-N 0.000 description 1
- VMBAUQZYJZISFO-UHFFFAOYSA-N Cc(cc1)ccc1S(=O)=O Chemical compound Cc(cc1)ccc1S(=O)=O VMBAUQZYJZISFO-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 235000008526 Galium odoratum Nutrition 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- RDWZBWVDSHTXLT-ODHFDHEPSA-N Latanoprost Lactol Chemical compound C([C@@H](CC[C@@H]1[C@H]2CC(O)O[C@H]2C[C@H]1O)O)CC1=CC=CC=C1 RDWZBWVDSHTXLT-ODHFDHEPSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N NC(c1ccccc1)=O Chemical compound NC(c1ccccc1)=O KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- YMJHOAUMNKJHNV-QFIPXVFZSA-N Nc(ccc1c2cccc1)c2-c1c(cccc2)c2ccc1NC([C@H]1NCCC1)=O Chemical compound Nc(ccc1c2cccc1)c2-c1c(cccc2)c2ccc1NC([C@H]1NCCC1)=O YMJHOAUMNKJHNV-QFIPXVFZSA-N 0.000 description 1
- MTNPITXJKLMSKU-BQBZGAKWSA-N O=C(C1)O[C@@H]2[C@H]1C=CCC2 Chemical compound O=C(C1)O[C@@H]2[C@H]1C=CCC2 MTNPITXJKLMSKU-BQBZGAKWSA-N 0.000 description 1
- KOKVEWYMKVYINV-UTGOTEENSA-N OC([C@H]1NCCC1)([AlH2])[AlH2] Chemical compound OC([C@H]1NCCC1)([AlH2])[AlH2] KOKVEWYMKVYINV-UTGOTEENSA-N 0.000 description 1
- HAXSVQYBWAUFLM-TWUYJFSISA-N O[C@@H](CCc1ccccc1)/C=C/[C@H]([C@@H]1[C@H](C2)OCC1)[C@@H]2O Chemical compound O[C@@H](CCc1ccccc1)/C=C/[C@H]([C@@H]1[C@H](C2)OCC1)[C@@H]2O HAXSVQYBWAUFLM-TWUYJFSISA-N 0.000 description 1
- HNPFPERDNWXAGS-NFVOFSAMSA-N O[C@H](CC[C@H]([C@@H](C/C=C\CCCC(O)=O)[C@H](C1)O)[C@@H]1O)CCc1ccccc1 Chemical compound O[C@H](CC[C@H]([C@@H](C/C=C\CCCC(O)=O)[C@H](C1)O)[C@@H]1O)CCc1ccccc1 HNPFPERDNWXAGS-NFVOFSAMSA-N 0.000 description 1
- BBRBUTFBTUFFBU-LHACABTQSA-N Ornoprostil Chemical compound CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CC(=O)CCCCC(=O)OC BBRBUTFBTUFFBU-LHACABTQSA-N 0.000 description 1
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- HVVNJUAVDAZWCB-YFKPBYRVSA-N [(2s)-pyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1 HVVNJUAVDAZWCB-YFKPBYRVSA-N 0.000 description 1
- XDGQJDJYSPBMTE-SFYZADRCSA-N [O]#CC(C1)=C[C@@H]2[C@H]1OCC2 Chemical compound [O]#CC(C1)=C[C@@H]2[C@H]1OCC2 XDGQJDJYSPBMTE-SFYZADRCSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000005882 aldol condensation reaction Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000004808 allyl alcohols Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 229950002312 arbaprostil Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 1
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- JKLZCTYQZFXPSW-UHFFFAOYSA-N bicyclo[4.2.0]oct-4-en-8-one Chemical compound C1=CCCC2C(=O)CC21 JKLZCTYQZFXPSW-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 description 1
- PBGVMIDTGGTBFS-UHFFFAOYSA-N but-3-enylbenzene Chemical compound C=CCCC1=CC=CC=C1 PBGVMIDTGGTBFS-UHFFFAOYSA-N 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 229960004409 cloprostenol Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- FBCCMZVIWNDFMO-UHFFFAOYSA-N dichloroacetyl chloride Chemical compound ClC(Cl)C(Cl)=O FBCCMZVIWNDFMO-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- RHWCFZSKECSWSF-UHFFFAOYSA-N dimethyl 3-formyl-4-hydroxyheptanedioate Chemical compound COC(=O)CCC(O)C(CC(=O)OC)C=O RHWCFZSKECSWSF-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229950008992 dimoxaprost Drugs 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950007459 enisoprost Drugs 0.000 description 1
- 229960003559 enprostil Drugs 0.000 description 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- XFHGDBFMJCLEOW-UHFFFAOYSA-N ethoxyethane;trifluoroborane;hydrofluoride Chemical compound F.FB(F)F.CCOCC XFHGDBFMJCLEOW-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- FNKQFBWKNIGIOS-UHFFFAOYSA-N furan-2,5-diol Chemical compound OC1=CC=C(O)O1 FNKQFBWKNIGIOS-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- KYBOHGVERHWSSV-VNIVIJDLSA-N gemeprost Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC KYBOHGVERHWSSV-VNIVIJDLSA-N 0.000 description 1
- 229960003480 gemeprost Drugs 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- OJZYRQPMEIEQFC-UAWLTFRCSA-N limaprost Chemical compound CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O OJZYRQPMEIEQFC-UAWLTFRCSA-N 0.000 description 1
- 229950009365 limaprost Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229950006294 meteneprost Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- ZZVPHCPLTZTOBC-BZXXIRPUSA-N methyl (e)-7-[(1r,2r,3r)-2-[(1e,5e)-6-(cyclopenten-1-yl)-4-hydroxy-4-methylhexa-1,5-dienyl]-3-hydroxy-5-oxocyclopentyl]hept-4-enoate Chemical compound O[C@@H]1CC(=O)[C@H](CC/C=C/CCC(=O)OC)[C@H]1\C=C\CC(C)(O)\C=C\C1=CCCC1 ZZVPHCPLTZTOBC-BZXXIRPUSA-N 0.000 description 1
- TWCQWABAGCMHLL-ROVQGQOSSA-N methyl (z)-7-[(1r,2r,3r)-2-[(e)-4-ethenyl-4-hydroxyoct-1-enyl]-3-hydroxy-5-oxocyclopentyl]hept-5-enoate Chemical compound CCCCC(O)(C=C)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(=O)OC TWCQWABAGCMHLL-ROVQGQOSSA-N 0.000 description 1
- CIBHDGPIOICRGX-ZQCHCGQNSA-N methyl (z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]hept-4-enoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CC\C=C/CCC(=O)OC CIBHDGPIOICRGX-ZQCHCGQNSA-N 0.000 description 1
- DLZVZNAPRCRXEG-UHFFFAOYSA-N methyl 4-oxobutanoate Chemical compound COC(=O)CCC=O DLZVZNAPRCRXEG-UHFFFAOYSA-N 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- GGDWDKDPRJFMHD-ZXYUVVQBSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4-methoxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(OC)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC GGDWDKDPRJFMHD-ZXYUVVQBSA-N 0.000 description 1
- PTOJVMZPWPAXER-VFJVYMGBSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]hepta-4,5-dienoate Chemical compound O[C@@H]1CC(=O)[C@H](CC=C=CCCC(=O)OC)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 PTOJVMZPWPAXER-VFJVYMGBSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229950000086 mexiprostil Drugs 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- COCAUCFPFHUGAA-MGNBDDOMSA-N n-[3-[(1s,7s)-5-amino-4-thia-6-azabicyclo[5.1.0]oct-5-en-7-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]23N=C(SCC[C@@H]2C3)N)=CC=1NC(=O)C1=CC=C(Cl)C=N1 COCAUCFPFHUGAA-MGNBDDOMSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- RGGPDHHEMZDRQW-UHFFFAOYSA-N n-benzyl-1-phenylmethanamine;2,2,2-trifluoroacetic acid Chemical compound [O-]C(=O)C(F)(F)F.C=1C=CC=CC=1C[NH2+]CC1=CC=CC=C1 RGGPDHHEMZDRQW-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229950003144 nocloprost Drugs 0.000 description 1
- KPMKEVXVVHNIEY-RITPCOANSA-N norcamphor Chemical compound C1C[C@@H]2C(=O)C[C@H]1C2 KPMKEVXVVHNIEY-RITPCOANSA-N 0.000 description 1
- FPXPWFLCGOFSTQ-UHFFFAOYSA-N oct-6-en-2-one Chemical compound CC=CCCCC(C)=O FPXPWFLCGOFSTQ-UHFFFAOYSA-N 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229950009738 ornoprostil Drugs 0.000 description 1
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- HVAMZGADVCBITI-UHFFFAOYSA-N pent-4-enoic acid Chemical compound OC(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- PMOIAJVKYNVHQE-UHFFFAOYSA-N phosphanium;bromide Chemical compound [PH4+].[Br-] PMOIAJVKYNVHQE-UHFFFAOYSA-N 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 229950005226 remiprostol Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- SPOAFZKFCYREMW-FWYLUGOYSA-N rioprostil Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCCO SPOAFZKFCYREMW-FWYLUGOYSA-N 0.000 description 1
- 229950004712 rioprostil Drugs 0.000 description 1
- NMAOJFAMEOVURT-RTKIROINSA-N rosaprostol Chemical compound CCCCCC[C@H]1CCC(O)[C@@H]1CCCCCCC(O)=O NMAOJFAMEOVURT-RTKIROINSA-N 0.000 description 1
- 229950003055 rosaprostol Drugs 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- UQZVCDCIMBLVNR-TWYODKAFSA-N sulprostone Chemical compound O[C@@H]1CC(=O)[C@H](C\C=C/CCCC(=O)NS(=O)(=O)C)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 UQZVCDCIMBLVNR-TWYODKAFSA-N 0.000 description 1
- 229960003400 sulprostone Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229950002177 taprostene Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- JUYWTMASJNJBHK-MRXNPFEDSA-N tert-butyl-dimethyl-[(3s)-5-phenylpent-1-yn-3-yl]oxysilane Chemical compound CC(C)(C)[Si](C)(C)O[C@H](C#C)CCC1=CC=CC=C1 JUYWTMASJNJBHK-MRXNPFEDSA-N 0.000 description 1
- MMKOSVMWXHDGEI-CYBMUJFWSA-N tert-butyl-dimethyl-[(3s)-oct-1-yn-3-yl]oxysilane Chemical compound CCCCC[C@@H](C#C)O[Si](C)(C)C(C)(C)C MMKOSVMWXHDGEI-CYBMUJFWSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229950010528 tiprostanide Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 1
- 229950008298 trimoprostil Drugs 0.000 description 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 description 1
- 229960004317 unoprostone Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229950011361 viprostol Drugs 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a compound of formula (I) as defined below, a process for making a compound of formula (I), and a process for making a prostaglandin or a prostaglandin analogue using a compound of formula (I).
- Prostaglandins are hormone-like chemical messengers that regulate a host of physiological activities essential to life, such as the contraction and relaxation of smooth muscle tissue, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.
- prostaglandins are derived from arachidonic acid (AA) and transformed by prostaglandin synthetase into a number of structurally related carbocyclic molecules. These sensitive and labile molecules are not stored in the body but are synthesized in response to stimuli. They were first discovered in the early 1930s by von Euler and by the mid 1960s the structures of the first family of prostaglandins was uncovered by Bergstrom et al.
- prostaglandins are widely used as pharmaceuticals and some have become billion dollar drugs, such as latanoprost, an analogue of the prostaglandin PGF 2a , which is used in the treatment of glaucoma.
- prostaglandins still require lengthy syntheses.
- the other members of the family of prostaglandins can be assembled from this lactone; prostaglandin PGF 2a , for example, can be assembled from the Corey lactone in 8 further steps, i.e. in 17 steps from cyclopentadiene.
- prostaglandins Despite the enantioselective tools available to modern synthetic chemists, a more efficient synthesis for manufacturing prostaglandins has remained elusive. Most if not all of the currently available ways of manufacturing prostaglandins require lengthy syntheses where every step costs time and money, generates waste, and is invariably accompanied by material losses. A need remains for new methods of synthesizing prostaglandins which are more efficient and less expensive than the existing syntheses.
- prostaglandins including both the naturally occurring prostaglandins, such as PGF 2a , and their synthetic analogues, such as latanoprost.
- Z is OR 10 , NR"R", SR 11 , S(0)R 11 , S0 2 R 11 ,
- R 10 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, CO-R 11 , or a protecting group, and
- R is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or alkoxyl.
- the groups R 11 may be the same or different from each other.
- Formula (I) encompasses a new key intermediate, lactol (la), wherein Z is OR 10 and R 10 is H, and its functionalized and/or protected forms.
- This new key intermediate allows significantly shorter synthetic routes to a range of naturally occurring prostaglandins, such as PGF 2a , and to their synthetic analogues, such as latanoprost.
- the new key intermediate can be synthesized in only one reaction from succinaldehyde with very high enantioselectivity. The successful outcome of this reaction was highly surprising, in view of the very large number of alternative reaction pathways available to highly reactive succinaldehyde (which has two reactive aldehyde groups on each molecule), as discussed in more detail under the second aspect of the invention below.
- An "optionally substituted” group may be unsubstituted, or substituted with one or more, for example one or two, substituents.
- substituents may for example be selected from alkyl, cycloalkyi, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl groups; carboxylic acids and carboxylate ions; carboxylate esters; carbamates; alkoxyl groups; ketone and aldehyde groups; amine and amide groups; -OH; -CN; -N0 2 ; and halogens.
- An alkyl group may be a straight or branched chain alkyl group.
- the alkyl group may contain up to 20 carbon atoms.
- the alkyl group may be CI to C6 alkyl, or CI to C4 alkyl, or CI to C3 alkyl, or CI to C2 alkyl.
- a cycloalkyi group may contain up to 8 carbon atoms.
- An alkenyl group may be a straight or branched chain alkenyl group.
- the alkenyl group may contain up to 20 carbon atoms.
- the alkenyl group may be C2 to C6 alkenyl, or C2 to C4 alkenyl.
- An alkynyl group may be a straight or branched chain alkynyl group.
- the alkynyl group may contain up to 20 carbon atoms.
- the alkynyl group may be C2 to C6 alkynyl, or C2 to C4 alkynyl.
- An aryl group may be a monocyclic or bicyclic aromatic group.
- the aryl group may contain from 5 to 12 carbon atoms.
- a heteroaryl group may be a monocyclic or bicyclic group.
- the heteroaryl group may contain from 1 to 12 carbon atoms and one or more N, O or S atoms.
- the heteroaryl group may be a 5 or 6-membered ring containing one or more N atoms.
- a heterocyclyl group may be a monocyclic or bicyclic group.
- the heterocyclyl group may contain from 1 to 12 carbon atoms and one or more N, O or S atoms.
- protecting group means a group capable of protecting an oxygen atom, which protecting group may, subsequent to the reaction for which protection is employed, be removed without disturbing the remainder of the molecule.
- protecting groups are well known and listed in standard texts such as Kocienski P. 1, Protecting Groups, 3rd ed., Georg Thieme Verlag, New York, 2005; and Greene T. W., Wuts P. G. M., Protective Groups In Organic Synthesis, 3rd ed., John Wiley & Sons, New York, 1998.
- the protecting group can make the chemical moiety, which consists of an oxygen atom and the protecting group, unavailable for a reaction with an organometallic reagent.
- R is CI to C6 alkyl.
- R is methyl, ethyl or t-butyl.
- R 10 is methyl or t-butyl.
- R 10 is methyl substituted with a phenyl group, i.e. R 10 is benzyl.
- R 10 is optionally substituted benzyl.
- R 10 is cyclohexyl or cyclopentyl.
- R 10 is cyclohexyl or cyclohexyl substituted with one or more alkyl groups, such as for example one or more C1-C6 alkyl groups.
- R 10 is menthyl (2-isopropyl-5-methylcyclohexyl).
- R 10 is phenyl. In an embodiment, R 10 is phenyl substituted with one or more substituents including phenyl. In an embodiment, R 10 is phenyl substituted with phenyl. In an embodiment, R 10 is a monocyclic or bicyclic aromatic group containing from 5 to 12 carbon atoms.
- R 10 is CO-R 11 and R 11 is phenyl, i.e. R 10 is benzoyl. In an embodiment, R 10 is optionally substituted benzoyl.
- R 10 is a protecting group selected from benzyl, benzoyl, methoxymethyl (MOM), methoxyethoxymethyl ether (MEM), tetrahydropyranyl (THP), and silicon protecting groups such as, for example, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), triphenylsilyl (TPS), t-butyld i methylsi lyl (TBDMS), t-butyldiphenylsilyl (TBDPS),
- TMS trimethylsilyl
- TES triethylsilyl
- TIPS triisopropylsilyl
- TPS triphenylsilyl
- TDMS t-butyld i methylsi lyl
- TDPS t-butyldiphenylsilyl
- Y is
- Y is
- R 10 is optionally substituted alkyl.
- R is methyl.
- the chiral secondary amine catalyst has the following structure:
- R 1 and R 2 are optionally substituted alkyl groups, or R 1 and R 2 are linked to form part of an optionally substituted 4-, 5- or 6-membered heterocycle;
- X 1 is 0, S or NR 3 , wherein R 3 is an alkyl group, or R 3 is linked with R 4 to form part of a 5- or 6-membered ring which may contain one or more further N atoms;
- X 2 is 0 or NR 4 , wherein R 4 is haloalkyi (preferably CF 3 ), aryl substituted with one or more halogens or haloalkyi groups (preferably CF 3 ), S0 2 R 5 , or R 4 is linked with R 3 to form part of a 5- or 6-membered ring which may contain one or more further N atoms, and R 5 is an optionally substituted alkyl group, an optionally substituted cycloalkyi group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, or an optionally substituted heterocyclyl group;
- n is an integer from 1 to 5;
- n is an integer from 1 to 5;
- each R 9 is independently selected from an electron-withdrawing group (such as for example a halogen, a haloalkyl (preferably CF 3 ), N0 2 or CN) and an optionally substituted alkyl, and at least one R 9 on each phenyl ring is an electron-withdrawing group (such as for example a halogen, a haloalkyl (preferably CF 3 ), N0 2 or CN);
- an electron-withdrawing group such as for example a halogen, a haloalkyl (preferably CF 3 ), N0 2 or CN
- the acidic co-catalyst is selected from [Bn 2 NH 2 ][OCOCF 3 ], [Bn 2 NH 2 ][BF 4 ],
- R 3 and R 4 are linked to form part of a 5- or 6-membered ring, it is possible for R 3 and/or R 4 to be a nitrogen atom.
- the process of the invention gives access to a new key intermediate, lactol (la), which allows significantly shorter synthetic routes to a range of naturally occurring prostaglandins, such as PGF 2a , and to their synthetic analogues, such as latanoprost.
- the new key intermediate can be synthesized in only one reaction from succinaldehyde with very high enantioselectivity.
- very high enantioselectivity means that the desired enantiomer is formed in at least 80:20 e.r. (60% ee), at least 85:15 e.r. (70% ee), at least 90:10 e.r. (80% ee), at least 91:9 e.r.
- aldol product 10 is required to form the less favoured hemiacetal 11 rather than hemiacetal 12.
- Hemiacetal 11 is required to undergo an intramolecular second aldol reaction and eliminate to give (la), but aldol 10 itself should not eliminate to give 13.
- aldol 10 is a reactive trialdehyde which will be prone to undergo further aldol reactions with succinaldehyde (II) or with itself, leading to 14 and 15 and ultimately oligomers.
- the chiral secondary amine catalyst catalyses the enantioselective conversion of succinaldehyde (II) to trialdehyde product 10.
- Product 10 may equilibrate to form a small amount of dialdehyde 11, and it is postulated that the acidic co-catalyst catalyses the conversion of any dialdehyde 11 to the desired lactol (la).
- the acidic co-catalyst is added to the reaction mixture after the chiral secondary amine catalyst has been added. Significant improvements in yield were observed using a staggered addition of the catalysts.
- the acidic co-catalyst is ZnCI 2 , Zn(OTf) 2 , Amberlite 120, or Montmorillonite K10
- the acidic co-catalyst is preferably added to the reaction mixture after the chiral secondary amine catalyst has been added.
- the optimum delay to add the acidic co-catalyst, after the chiral secondary amine catalyst has been added to the reaction mixture was found to be dependent on the amount of chiral secondary amine catalyst employed, the temperature and the concentration, and can readily be established by routine experimentation.
- the acidic co-catalyst is added to the reaction mixture at least 2 hours after the chiral secondary amine catalyst has been added.
- the acidic co-catalyst is added to the reaction mixture at least 8 hours after the chiral secondary amine catalyst has been added.
- the chiral secondary amine catalyst has structure (A) or (B) as set out above.
- R 1 and R 2 are linked to form part of an optionally substituted 4-, 5- or 6- membered heterocycle.
- the substituents may also be joined with the 4-, 5- or 6-membered heterocycle to form fused rings.
- the optionally substituted 4-, 5- or 6-membered heterocycle comprises, in addition to the N atom, at least one further heteroatom selected from N, S and/or 0.
- R 1 and R 2 are linked to form part of an optionally substituted 4- or 5- membered heterocycle.
- the 4- or 5-membered heterocycle is selected from pyrrolidine, thiazolidine, oxazolidine and azetidine.
- R 1 and R 2 are linked to form part of an optionally substituted 5-membered heterocycle.
- the 5-membered heterocycle is selected from pyrrolidine, thiazolidine and oxazolidine.
- the 5-membered heterocycle is pyrrolidine.
- the chiral secondar catalyst has structure (A):
- R 1 , R 2 , X 1 and X 2 are as defined above.
- the chiral secondary amine catalyst comprises any one of the following compounds:
- the chiral secondary amine catalyst comprises the compound:
- X 1 is 0 or NR 3 , wherein R 3 is as defined above.
- the chiral secondary amine catalyst has the following structure:
- X 1 is 0 or NR 3 , wherein R 3 is an alkyl group, or R 3 is linked with R 4 to form part of a 5- or 6-membered ring which may contain one or more further N atoms;
- X 2 is 0 or NR 4 , wherein R 4 is S0 2 R 5 , or R 4 is linked with R 3 to form part of a 5- or 6- membered ring which may contain one or more further N atoms, and R 5 is an alkyl group or an aryl group;
- n is an integer from 0 to 7;
- each R 6 is independently selected from -OR 7 , optionally substituted alkyl, optionally substituted cycloalkyi, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or -CO- R 8 ,
- R 7 is H, optionally substituted alkyl, optionally substituted cycloalkyi, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, CO-R 8 , or a protecting group, and
- R 8 is optionally substituted alkyl, optionally substituted cycloalkyi, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or alkoxyl.
- R 6 two groups R 6 may also be joined together to form fused rings.
- n is 0, 1, 2, 3, 4, 5, 6 or 7.
- n is 0 or 1.
- X 1 is O.
- X 2 is O.
- X 1 is 0 and X 2 is 0.
- R 6 is -OR 7 , wherein R 7 is H, an alkyl group, -CO-R 8 ,
- R 8 is an alkyl group.
- R 7 is a protecting group selected from methoxymethyl (MOM), trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), triphenylsilyl (TPS), t- butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), (dimethyl)thexylsilyl, and 2- (trimethylsilyl)ethoxymethyl (SEM).
- MOM methoxymethyl
- TMS trimethylsilyl
- TES triethylsilyl
- TIPS triisopropylsilyl
- TPS triphenylsilyl
- TDMS t- butyldimethylsilyl
- TDPS t-butyldiphenylsilyl
- SEM 2- (trimethylsilyl)ethoxymethyl
- R 6 is a hydroxyl group, -O-t-butyl or acetyl.
- the chiral secondary amine catalyst comprises any one of the following compounds:
- the chiral secondary amine catalyst comprises any one of the following compounds:
- the chiral secondary amine catalyst comprises any one of the following compounds:
- the chiral secondary amine catalyst comprises (S proline, which has the structure:
- the chiral secondary amine catalyst has structure (B):
- the chiral secondary amine catalyst comprises any one of the following compounds:
- the acidic co-catalyst has the structure [ ⁇ ][ ⁇ ] wherein [a] is a cation selected from [Bn 2 NH 2 ] + , [BnNH 3 ] + , [pyridinium] + , [2,2'-bipyridinium] + , [2,2':6',2"- terpyridinium] + , [morpholinium] + and [thiomorpholinium] + , and [ ⁇ ] is an anion selected from [F]-, [CI] “ , [Br] " , [I] " , [OCOCF3] " , [BF4] “ , [OCOCHC ] “ , and [0-C 6 H 3 -2,4-(N0 2 )2] ⁇ .
- the acidic co-catalyst comprises a cation selected from [(Bn) 2 NH 2 ] + , [BnNH 3 ] + and [pyridinium] + . In an embodiment, the acidic co-catalyst comprises a cation of the formula [(Bn) 2 NH 2 ] + .
- the acidic co-catalyst comprises a cation of the formula [BnNH 3 ] + .
- the acidic co-catalyst comprises a cation which is [pyridinium] + .
- the acidic co-catalyst comprises an anion of the formula [OCOCF 3 ] ⁇ .
- the acidic co-catalyst comprises [Bn 2 NH 2 ][OCOCF 3 ].
- [Bn 2 NH 2 ][OCOCF 3 ] was found to be the most effective of the co-catalysts tested, resulting in the highest yield of lactol (la).
- the acidic co-catalyst comprises a Bronsted acid.
- the catalyst loading of the chiral secondary amine catalyst is from 1 mol% to 20 mol% with respect to succinaldehyde (II). In an embodiment, the catalyst loading of the chiral secondary amine catalyst is from 1 mol% to 15 mol%, from 1 mol% to 10 mol%, from 1 mol% to 5 mol%, from 2 mol% to 20 mol%, from 2 mol% to 15 mol%, from 2 mol% to 10 mol%, from 2 mol% to 5 mol%, or around 2 mol% with respect to succinaldehyde (II).
- the catalyst loading of the acidic co-catalyst is from 0.05 mol% to 20 mol% with respect to succinaldehyde (II). In an embodiment, the catalyst loading of the acidic co-catalyst is from 0.05 mol% to 15 mol%, from 0.05 mol% to 10 mol%, from 0.05 mol% to 5 mol%, from 1 mol% to 20 mol%, from 1 mol% to 15 mol%, from 1 mol% to 10 mol%, from 1 mol% to 5 mol%, from 2 mol% to 20 mol%, from 2 mol% to 15 mol%, from 2 mol% to 10 mol%, from 2 mol% to 5 mol%, or around 2 mol% with respect to
- the key step of forming lactol (la) from succinaldehyde (II) is performed at a concentration of from 0.2 M to 4 M. These concentrations are calculated based on the amount of succinaldehyde present at the start of the reaction.
- the reaction is performed at a concentration of around 2 M, and at the stage after the acidic co-catalyst has been added the reaction is performed at a concentration of around 1 M .
- concentrations are calculated based on the amount of succinaldehyde present at the start of the reaction.
- a suitable solvent system is a solvent system which is capable of dissolving succinaldehyde (II), the chiral amine catalyst and the acidic co-catalyst at least to the extent which allows the key step to proceed to form lactol (la).
- a suitable solvent system can readily be established by routine experimentation.
- the solvent system comprises an organic solvent other than an alcohol.
- the solvent system comprises an aprotic organic solvent.
- the solvent system comprises tetrahydrofuran (THF), 2- methyltetrahydrofuran, dimethylsulfoxide (DMSO), acetonitrile, ethers such as te ⁇ -butyl methyl ether and dimethyl ether (DME), dioxane, toluene, dichloromethane (DCM), dimethoxyethane (DME), formamide, dimethylformamide (DMF), dimethylacetamide, N- methyl-2-pyrrolidone (NMP), sulfolane, esters such as methyl acetate, ethyl acetate, propyl acetate (n-propyl acetate or /-propyl acetate) and butyl acetate (n-butyl acetate, /-butyl acetate, t-butyl acetate or sec-butyl acetate), or a combination thereof.
- THF tetrahydrofuran
- the solvent system comprises tetrahydrofuran (THF) or 2- methyltetrahydrofuran, or a combination thereof.
- the solvent system comprises tetrahydrofuran (THF).
- the solvent system comprises less than 50 mol% water with respect to succinaldehyde (II).
- the solvent system comprises less than 25 mol% water with respect to succinaldehyde (II).
- succinaldehyde (II) As can be seen from the Examples (see Example 2, Procedure 7), the key step of forming lactol (la) from succinaldehyde (II) was found to tolerate this amount of water without a decrease in yield. This reaction therefore does not require anhydrous conditions; the use of reagent grade THF gives the same yield as the use of anhydrous THF.
- the solvent system comprises water in the presence of 20 mol% or more of triethanolamine relative to succinaldehyde (II).
- the key step is conducted at a temperature of from -10 °C to 40 °C. In an embodiment, the key step is conducted at a temperature of from -10 °C to 30 °C, from -10 °C to 25 °C, from 0 °C to 40 °C, from 0 °C to 30 °C, from 0 °C to 25 °C, from 10 °C to 40 °C, from 10 °C to 30 °C, from 10 °C to 25 °C, or around room temperature.
- Root temperature is defined as from 16 to 22 or 25 °C, or from 18 to 22 or 25 °C, for example about 20 °C or about 25 °C.
- the reaction is performed for a time period between 15 minutes and 48 hours.
- the reaction in particular where the acidic co-catalyst is added to the reaction mixture after the chiral secondary amine catalyst has been added, at the stage before the acidic co- catalyst has been added the reaction is performed for a time period between 15 minutes and 48 hours, and at the stage after the acidic co-catalyst has been added the reaction is performed for a time period between 15 minutes and 48 hours.
- the acidic co-catalyst is added to the reaction mixture after the chiral secondary amine catalyst has been added, the chiral secondary amine catalyst is fS proline, and the acidic co-catalyst is [Bn 2 NH 2 ][OCOCF 3 ].
- the solvent system comprises tetrahydrofuran (THF) or 2-methyltetrahydrofuran, or a combination thereof.
- the catalyst loading of the chiral secondary amine catalyst is around 2 mol% with respect to succinaldehyde (II), and the catalyst loading of the acidic co-catalyst is around 2 mol% with respect to succinaldehyde (II).
- the acidic co-catalyst is added to the reaction mixture around 8 hours after the chiral secondary amine catalyst has been added.
- these conditions were found to be the most effective of those tested, resulting in the highest yield of lactol (la) if the reaction is performed around the scale used in the Examples. From this starting point, for different reaction scales the optimum catalyst loadings and the optimum delay to add the acidic co-catalyst can readily be established by routine experimentation.
- the process before the key step, further comprises a preceding step of heating 2,5-disubstituted tetrahydrofuran (III) in water to form succinaldehyde (II), in accordance with the following reaction scheme:
- R 40 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or -COR 41 , where R 41 is alkyl.
- R 40 is Ci-C 4 alkyl. In an embodiment, R 40 is methyl or ethyl. In an embodiment, R 40 is methyl.
- the preceding step is conducted in the absence of acid.
- a hydrolysis of 2,5-dimethoxytetrahydrofuran is known, but acid is generally required, which can interfere with the subsequent aldol reaction, and purification can be difficult.
- the material obtained by the known method requires purification by distillation, often more than once, unlike the material obtained in the preceding step described above.
- the preceding step results in the formation of an alcohol R 40 -OH.
- the preceding step comprises evaporating the formed alcohol R 40 -OH.
- the preceding step comprises a change of the solvent system from water to a new solvent system suitable for the key step, as described above, resulting in the formation of a solution of succinaldehyde (II) in the new solvent system.
- the preceding step may be carried out in situ, which can result in a one-pot conversion of the 2,5-disubstituted tetrahydrofuran (III) to the lactol (la) (as shown for 2,5-dimethoxytetrahydrofuran in .Examples 3D, 3E, 3F and 3H).
- the solvent system is changed from water to a solvent system comprising an organic solvent selected from tetrahydrofuran (THF), 2-methyltetrahydrofuran, toluene, ethyl acetate, methyl acetate, and combinations thereof.
- THF tetrahydrofuran
- 2-methyltetrahydrofuran 2-methyltetrahydrofuran
- toluene ethyl acetate
- methyl acetate methyl acetate
- the change of solvent system is achieved by using a Dean-Stark apparatus.
- the process further comprises a subsequent step of functionalising lactol (la) to give a compound of formula (lb):
- Z 1 is OR 20 , NR n R n , SR 11 , S(0)R n , S0 2 R n ,
- R 20 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, CO-R 11 , or a protecting group, and R 11 is as defined above for the first aspect of the invention.
- the groups R 11 may be the same or different from each other.
- R 20 is CI to C6 alkyl. In an embodiment, R 20 is methyl, ethyl or t-butyl. In an embodiment, R 20 is methyl or t-butyl. In an embodiment, R 20 is methyl substituted with a phenyl group, i.e. R 20 is benzyl.
- R 20 is cyclohexyl or cyclopentyl. In an embodiment, R 20 is cyclohexyl or cyclohexyl substituted with one or more alkyl groups, such as for example one or more C1-C6 alkyl groups. In an embodiment, R 20 is menthyl (2-isopropyl-5-methylcyclohexyl). In an embodiment, R 20 is phenyl. In an embodiment, R 20 is phenyl substituted with one or more substituents including phenyl. In an embodiment, R 20 is phenyl substituted with phenyl. In an embodiment, R 20 is a monocyclic or bicyclic aromatic group containing from 5 to 12 carbon atoms.
- R 20 is CO-R 11 and R 11 phenyl, i.e. R 20 is benzoyl.
- R is a protecting group selected from benzyl, benzoyl, methoxymethyl (MOM), methoxyethoxymethyl ether (MEM), tetrahydropyranyl (THP), and silicon protecting groups such as, for example, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), triphenylsilyl (TPS), t-butyld i methylsi lyl (TBDMS), t-butyldiphenylsilyl (TBDPS),
- the compound of formula (lb) can be purified using purification techniques known in the art, such as, for example, column chromatography.
- the compound of formula (lb) can advantageously be purified by a purification with sodium bisulfite.
- Purification of aldehydes with sodium bisulfite allows aldehydes in a solution to precipitate as the bisulfite adduct, which can be isolated by filtration.
- the bisulfite adduct can be reconverted to the aldehyde as required.
- Purification of the compound of formula (lb) with sodium bisulfite may allow the compound of formula (lb) to be purified in the absence of column chromatography, which may assist the scale up of the process.
- the resulting bisulfite adduct may have improved storage properties.
- a process for making a prostaglandin or a prostaglandin analogue which uses a compound of formula (I) as defined above as a reactant.
- prostaglandin analogue means a molecule which binds to a prostaglandin receptor, and which therefore shares a number of features with naturally occurring prostaglandins.
- Such molecules include, for example, latanoprost, bimatoprost, travoprost, unoprostone, cloprostenol, sulprostone, enprostil, misoprostil, nocloprost, arbaprostil, rioprostil, mexiprostil, ornoprostil, rosaprostol, limaprost, gemeprost, beraprost, enisoprost, tiprostanide, remiprostol, meteneprost, viprostol, dimoxaprost, trimoprostil, taprostene and GR-63779X.
- the acetal of formula (Ic) is formed by protecting lactol (la), in accordance with the following reaction scheme:
- the acetal of formula (Ic) can be purified using purification techniques known in the art, such as, for example, column chromatography.
- the acetal of formula (Ic) can advantageously be purified by a purification with sodium bisulfite, as discussed above.
- the lactol (la) is formed by treating succinaldehyde (II), in accordance with the key step in the process of the second aspect of the invention, with (i) a chiral secondary amine catalyst and (ii) an acidic co-catalyst, in accordance with the following reaction scheme:
- the process of the third aspect of the invention comprises the steps of:
- step (d) subjecting the compound formed in step (c) to oxidative cleavage, followed by reduction;
- step (f) reacting the compound formed in step (e) with an olefination reagent to give a desired side chain at position p 2 , to form a prostaglandin or a prostaglandin analogue.
- this process includes optional step (b).
- this process includes optional steps (a) and (b).
- the olefination reagent in step (f) is a Wittig reagent.
- the process of the third aspect of the invention is a process for making PGF 2a , which comprises the steps of:
- R PG1 and R re2 are protecting groups
- A is a group which allows the compound of formula (IV) to react as a soft nucleophile via a Michael addition
- Hal " is a halide group selected from iodide, bromide, chloride and fluoride.
- this process includes optional step (b). In an embodiment, this process includes optional steps (a) and (b).
- R is selected from silicon protecting groups such as, for example, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), triphenylsilyl (TPS), t- butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), (dimethyl)thexylsilyl, and 2- (trimethylsilyl)ethoxymethyl (SEM).
- TMS trimethylsilyl
- TES triethylsilyl
- TIPS triisopropylsilyl
- TPS trihenylsilyl
- TDMS t- butyldimethylsilyl
- TDPS t-butyldiphenylsilyl
- SEM 2- (trimethylsilyl)ethoxymethyl
- R PG2 is selected from optionally substituted benzyl, optionally substituted benzoyl (for example substituted with phenyl), tetrahydropyranyl (THP), acetate,
- methoxymethyl MCM
- methoxyethoxymethyl MEM
- ethoxyethyl ether EE
- silicon protecting groups such as, for example, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), triphenylsilyl (TPS), t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), (dimethyl)thexylsilyl, and 2-(trimethylsilyl)ethoxymethyl (SEM).
- TMS trimethylsilyl
- TES triethylsilyl
- TIPS triisopropylsilyl
- TPS trihenylsilyl
- TDMS t-butyldimethylsilyl
- TDPS t-butyldiphenylsilyl
- SEM 2-(trimethylsilyl)ethoxymethyl
- group A comprises a metal centre with one or more ligands. In an embodiment, group A comprises a Cu centre with one or more ligands.
- the soft nucleophile of formula (IV) is a cuprate reagent.
- the cuprate reagent is selected from a mixed higher order cuprate reagent, a heterocuprate reagent and a mixed homocuprate reagent.
- group A is
- L 1 is a ligand selected from thiophene, pyrrole, imidazole, optionally substituted phenyl, substituted acetylene, (alkylsulfinyl)alkyl and (alkylsulfonyl)alkyl; and
- L 2 is a ligand selected from CN, PhS, t-BuO, Ph 2 P, (C 6 Hn) 2 N, t-Bu 2 P, thiophene, pyrrole, imidazole, optionally substituted phenyl, substituted acetylene, (alkylsulfinyl)alkyl and
- the soft nucleophile of formula (IV) is a mixed higher order cuprate reagent and group A is
- L 1 is a ligand selected from thiophene, pyrrole, imidazole, optionally substituted phenyl, substituted acetylene, (alkylsulfinyl)alkyl and (alkylsulfonyl)alkyl.
- group A is selected from the following structures:
- group A has the following structure:
- the soft nucleophile of formula (IV) is a heterocuprate reagent and group A is
- the soft nucleophile of formula (IV) is a mixed homocuprate reagent and group A is
- L 2 is a ligand selected from thiophene, pyrrole, imidazole, optionally substituted phenyl, substituted acetylene, (alkylsulfinyl)alkyl and (alkylsulfonyl)alkyl.
- group A is
- L 2 is selected from the following structures:
- the oxidative cleavage in step (d) is ozonolysis.
- Protection, deprotection and reduction can be carried out in the usual ways known to the skilled person; these are routine steps in chemical synthesis.
- Hal " in formula (VIII) is selected from iodide, bromide and chloride.
- the phosphonium halide of formula (VIII) is a phosphonium bromide, i.e. Hal " in formula (VIII) is bromide.
- the process of the third aspect of the invention is a process for making latanoprost, which comprises the steps of:
- R PG1 and R re are as defined above;
- A is a group which allows the compound of formula (IV) to react as a soft nucleophile via a Michael addition
- this process includes optional step (b). In an embodiment, this process includes optional steps (a) and (b).
- step (b) results in an acetal of formula (Ic), which is a protected form of lactol (la).
- the soft nucleophile of formula (IV) is a cuprate reagent.
- the cuprate reagent is selected from a mixed higher order cuprate reagent, a heterocuprate reagent and a mixed homocuprate reagent.
- the oxidative cleavage in step (d) is ozonolysis.
- the alkylation in step (g) comprises reacting the compound of formula (IX) with a propyl halide.
- Protection, deprotection and reduction can be carried out in the usual ways known to the skilled person; these are routine steps in chemical synthesis.
- the process of the third aspect of the invention is a process for making bimatoprost, which comprises the steps of:
- R PG1 and R re2 are as defined above;
- A is a group which allows the compound of formula (IV") to react as a soft nucleophile via a Michael addition
- this process includes optional step (b). In an embodiment, this process includes optional steps (a) and (b).
- step (b) results in an acetal of formula (Ic), which is a protected form of lactol (la).
- the soft nucleophile of formula (IV") is a cuprate reagent.
- the cuprate reagent is selected from a mixed higher order cuprate reagent, a heterocuprate reagent and a mixed homocuprate reagent.
- Group A is as defined above.
- the oxidative cleavage in step (d) is ozonolysis.
- succinaldehyde (II) as a starting material in the preparation of a prostaglandin or a prostaglandin analogue via the process according to the third aspect of the invention.
- references to compound properties such as optical rotations are - unless stated otherwise - to properties measured under ambient conditions, i.e. at atmospheric pressure and at a temperature of from 16 to 22 or 25 °C, or from 18 to 22 or 25 °C, for example about 20 °C or about 25 °C.
- Figure 1 is a 1 H NMR spectrum of succinaldehyde 8.
- Figure 2 is a ⁇ NMR spectrum of succinaldehyde 8 showing signs of oligomer formation.
- Figure 3 is a ⁇ NMR spectrum of >50 g preparation of succinaldehyde 8 in THF.
- Figure 4 is a ⁇ NMR spectrum of a 200 mg screening reaction of succinaldehyde 8 with (S proline and [Bn 2 NH 2 ][OCOCF 3 ].
- Figure 5 shows a zoomed-in region of Figure 4, showing the aromatic H's of the internal standard (1,3,5-trimethoxybenzene) and the vinyl H's of lactol 7 used to determine the yield.
- Figure 6 is a graph showing the consumption of succinaldehyde 8 and formation of lactol 7 in a reaction with 2 mol% (S)-proline and 2 mol% [Bn 2 NH 2 ][OCOCF 3 ] which was added at 8 h, after dilution to 1 M.
- Figure 7 is a ⁇ NMR of the crude reaction mixture from the 57.5 g scale reaction in Example 3A.
- Figure 8 shows a zoomed-in region of Figure 7 showing peaks used for yield calculation.
- Figure 9a shown a chiral GC trace corresponding to racemic material ( ⁇ )-7, minor diastereomer.
- Figure 9b shown a chiral GC trace corresponding to enantioenriched 7 from organocata lytic reaction, minor diastereoisomer.
- Figure 10 is a * ⁇ NMR spectrum of succinaldehyde 8 in 2-MeTHF with internal standard.
- Figure 11 is a zoomed-in region of the *H NMR of a reaction mixture corresponding to Table 11, entry 2, in .Example 8B(e), showing the aromatic H's of the internal standard (1,4- dimethoxybenzene) and the vinyl H of ( ⁇ )-20 used to determine the yield.
- diethyl ether, tetrahydrofuran and dichloromethane were obtained from a purification column composed of activated alumina (Pangborn et al., Organometallics 15, 1518-1520 (1996)) and reactions carried out under nitrogen using standard manifold techniques (the use of anhydrous solvents is explicitly stated in the experimental for these compounds). All chemicals were purchased from Acros, Aldrich, Alfa Aesar, Fluka, Lancaster or Merck and used without further purification unless otherwise stated. Triethylamine and trimethylsilyl chloride were distilled over CaH 2 under reduced pressure prior to use.
- IR data was obtained on a PerkinElmer Spectrum One FT-IR-spectrometer with only selected peaks being reported. Optical rotations were obtained on a Bellingham and Stanley Ltd. ADP 220 polarimeter. Melting points were determined using a Kofler hot stage apparatus and are uncorrected. Examples
- the reaction mixture after distillation of MeOH and water could be stored at -20 °C for over 2 weeks and extracted when required without detriment to the purity of the succinaldehyde.
- the CH 2 CI 2 extracts could be stored at -20 °C for 2 or 3 days before concentration without detriment to the purity of the succinaldehyde.
- the analytical data was consistent with the literature (House, H. O. etal., J. Org. Chem. 30, 1061-1070 (1965); Fakstorp, J. etal., J. Am. Chem. Soc. 72, 869-874 (1950); Hardy, P. M. etal., J. Chem. Soc, Perkin Trans. 2, 2270- 2278 (1972)).
- Example 2 General experimental procedures for investigations of proline-catalysed aldol reaction of succinaldehyde 8 A number of parameters were investigated for this reaction including solvent, different chiral secondary amine catalysts, different co-catalysts, stoichiometry of catalysts, timing, the effect of water and the effect of concentration, and these are described below.
- Penhoat reported a study of the effect of Lewis acids in the asymmetric aldol reaction, postulating aldehyde activation by the metal salt (Penhoat, M. et al., Tetrahedr. Lett. 52, 159- 162 (2011)). Among various Lewis acids screened in our conditions, only zinc chloride (entry 9) gave significant amounts of lactol 7.
- Acid 36 is described in Procedure 6 below.
- the use of an acid catalyst (with additive) in combination with (S)-proline from the beginning of the reaction led to a decrease in yield.
- solvent, proline loading, and [Bn 2 NH 2 ][OCOCF 3 ] loading we always observed a decrease in yield when [Bn 2 NH 2 ][OCOCF 3 ] was added at the start of the reaction, compared to addition after 2 hours.
- Figure 6 is a graph resulting from the monitoring of this reaction, showing the consumption of succinaldehyde 8 and formation of lactol 7 in a reaction with 2 mol% (S)-proline and 2 mol% [Bn 2 NH 2 ][OCOCF 3 ] which was added at 8 h, after dilution to 1 M.
- Figure 6 shows steady consumption of dialdehyde 8 during the initial phase with proline but no product formation until the addition of [Bn 2 NH 2 ][OCOCF 3 ] at 8 h.
- the lactol 7 is a compound according to the first aspect of the invention, and corresponds to compound (la) described above.
- the H NMR spectra in Figures 7 and 8 show a sample of the reaction mixture from 57.5 g scale reaction of succinaldehyde with (S)-proline and [Bn 2 NH 2 ][OCOCF 3 ] prior to work up.
- the sample was removed from reaction mixture, dissolved in DMSO-d6, and the THF evaporated under vacuum.
- the amount of lactol 7 present was calculated by comparison of the signals arising from the vinyl protons of the diastereoisomers of 7 with the signals of the internal standard, 1,3,5-trimethoxybenzene.
- the oil could be further purified with more rigorous column chromatography to give the lactol 7 as a light brown solid. After recrystallisation from petrol/EtOAc the lactol was obtained as pale brown needles. Mp 88-91 °C (after recrystallisation from petrol/EtOAc)
- This material was partially purified by chromatography (as described in Example 3A above) and the resultant material was then used for acetal formation. It was found that the addition of celite to the reaction mixture before removal of 2-MeTHF and/or THF allows 3 ⁇ 4 of this solvent to be removed rather than Vi while ensuring the resultant solids are very easy to filter (previous attempts to remove 3 ⁇ 4 of the solvent led to 'gluey' material when adding TBME). This modified procedure appears to lead to more oligomers being 'crashed out'/precipitated, allows even easier filtration of the oligomers, and leads to a cleaner product after chromatography.
- Example 3A The residue from Example 3A, containing 7, was dissolved in CH2CI2 (120 ml) and stirred at r.t.. MeOH (3.42 g, 4.33 ml, 107 mmol, 2.0 eq. based on ⁇ 16% of 7 detected by internal standard in Example 3A) was added via syringe. Amberlyst 15 (765 mg) and MgS0 4 (15.8 g) were added as solids in one portion and the reaction mixture was stirred at r.t. for 14 h. The reaction mixture was filtered through a sinter funnel and the solids washed with CH 2 CI 2 (2 x 30 ml).
- the filtrate was concentrated under reduced pressure and purified by column chromatography ( ⁇ 150 g silica), eluting with petrol/EtOAc (10:1 to 4: 1), to give the methyl acetal 24, (as an approximately 2:1 mixture of diasteroisomers, 7.85 g, 14% over 2 steps from succinaldehyde) as a yellow oil (this solidifies in the freezer, but the physical state and appearance differs depending on the exact ratio of diastereoisomers formed, one is a solid, the other an oil).
- the methyl acetal 24 is a compound according to the first aspect of the invention, and corresponds to compound (Ic) (and compound (lb)) described above.
- max CHC Vcnrr 1 2926, 2829, 1676, 1617, 1099, 1052, 1031, 978
- the reaction mixture was concentrated to the appropriate volume such that the concentration of the solution was 2 M (w.r.t. succinaldehyde 8, 135 ml for this example).
- (S)-Proline (622 mg, 5.40 mmol, 0.02 eq. w.r.t. succinaldehyde) was added and the reaction stirred at room temperature for 20 h.
- 2-Methyltetrahydrofuran (135 ml) was added to the reaction mixture followed by [Bn 2 NH 2 ][OCOCF 3 ] (1.68 g, 5.40 mmol) and the reaction stirred for a further 14 h at room temperature.
- TBME te/ ⁇ -Butyl methyl ether
- Example 3F The residue from Example 3F, containing 7, was dissolved in CH2CI2 (190 ml) and stirred at r.t.. MeOH (5.47 g, 6.90 ml, 170.6 mmol, 2.0 eq. based on ⁇ 13.4% of 7 detected by internal standard in the previous reaction) was added via syringe. Amberlyst 15 (1.22 g) and MgS0 4 (25.2 g) were added as solids in one portion and the reaction mixture was stirred at r.t. for 14 h. The reaction mixture was filtered through a sinter funnel and the solids washed with CH 2 CI 2 (3 x 60 ml).
- the filtrate was concentrated under reduced pressure and purified by column chromatography ( ⁇ 300 g silica), eluting with petrol/EtOAc (9:1 to 4:1), to give the methyl acetal 24, (as an approximately 2:1 mixture of diasteroisomers, 14.98 g, 14.0% (over 2 steps from succinaldehyde)) as a yellow oil (this solidifies in the freezer, but the physical state and appearance differs depending on the exact ratio of diastereoisomers formed, the major diastereoisomer is a solid, the minor an oil).
- the modified procedure for this scale (102.3 g) reduces the overall process time of the reaction (reduction of 1.5 h reaction time, 2-2.5 h for the distillation process and 1 h for the Dean-Stark process; total process time reduction: 4.5-5 h). Furthermore, high quality of dialdehyde (with minimum formation of oligomers) could be obtained when the distillation is performed at lower heating temperature (70 °C) under reduced pressure. Second step - succinaldehyde 8 to lactol 7
- Activated charcoal 100 g was added to the reaction and the volume of the reaction mixture was reduced by 1/2 under reduced pressure ( ⁇ 300 mL).
- te ⁇ -Butyl methyl ether 300 mL was added slowly (over ⁇ 15 mins) and with vigorous stirring of the mixture. Note: For the purposes of this example, slow addition of TBME helps to avoid the formation of oligomer aggregates.
- the mixture was stirred for 60 min before filtration of the resulting solids (through a sinter funnel; diameter: ⁇ 10 cm).
- Example 3H The residue from Example 3H, containing partially pure 7 (12.7 g, 82.3 mmol, 1 eq.) was dissolved in CH 2 CI 2 (187 ml) and stirred at r.t.. MeOH (10.6 g, 2.2 ml, 333 mmol, 4.0 eq.) was added via syringe. Amberlyst 15 (2.02 g) and MgS0 4 (41.0 g) were added as solids in one portion and the reaction mixture was stirred at r.t. for 15 h. The reaction mixture was filtered through a sinter funnel and the solids washed with CH 2 CI 2 (3 x 60 ml).
- Activated charcoal 70 g was added to the reaction and the volume of the reaction mixture was reduced by 1/2 under reduced pressure ( ⁇ 180 mL).
- te ⁇ -Butyl methyl ether 180 mL was added slowly (over ⁇ 15 mins) and with vigorous stirring of the mixture. Note: For the purposes of this example, slow addition of TBME helps to avoid the formation of oligomer aggregates.
- the mixture was stirred for 60 min before filtration of the resulting solids (through a sinter funnel; diameter: ⁇ 10 cm).
- the solids were washed with 2-MeTHF (3 x 120 ml or until the product was not observed in the filtrate by TLC, 1:1 petroleum ether/EtOAc) and the filtrate was concentrated under reduced pressure. Note: For the purposes of this example, the filtrate should not be concentrated to complete dryness, to help avoid solidifying the oligomers on the column, thereby clogging the column during the purification process.
- the filtrate was concentrated under reduced pressure and purified by column chromatography ( ⁇ 400 g silica), eluting with petroleum ether/EtOAc (10:1 to 4:1), to give the methyl acetal 24, (as an approximately 2:1 mixture of diastereoisomers, 4.86 g, 28.9 mmol, 16% (over 2 steps from succinaldehyde) as a yellow oil (this solidifies in the freezer, but the physical state and appearance differs depending on the exact ratio of diastereoisomers formed, the major diastereoisomer is a solid, the minor an oil, yields typically range between 16-18% for this reaction).
- Example 3J isolation of the lactol 7 leads to the use of less drying agent and MeOH.
- the cyclohexyl acetal 50 is a compound according to the first aspect of the invention, and corresponds to compound (Ic) (and compound (lb)) described above.
- max filmycnr 1 2940, 2912, 1680, 1667, 1614, 1365, 1338, 1194, 1157, 1094, 1053, 1026, 983, 965, 894, 866
- the filtrate was concentrated under reduced pressure and the excess cyclohexanol was removed by distillation at 65 °C under high vacuum. The residue was dissolved in hot pentane (20 ml), cooled to r.t. and filtered over celite. The filtrate was concentrated under reduced pressure, hexane (2 ml) and diethyl ether (4 ml) were added, followed by a crystal of pure acetal 50. The mixture was taken at -20 °C for 14 hours during which crystallization occurs. Solids were filtered over a cold (-20 °C) sintered glass funnel, washed with a cold (-20 °C) mixture of hexane/Et 2 0 (3:1) and dried under vacuum.
- Cyclohexyl acetal 50 (one diastereoisomer, 927.7 mg, 22% from lactol 7) was obtained as slightly brown crystals.
- the filtrate was concentrated under reduced pressure and dissolved in a hexane/Et 2 0 mixture (5:1). HBF 4 .OEt 2 (0.1 ml) is added via syringe and the mixture is kept at -20 °C for 14 hours.
- reaction mixture was filtered over a pad a silica, washed with petrol/EtOAc (10:1), and concentrated under vacuum. The excess of chloro(dimethyl)thexylsilane was removed by distillation at 50-55 °C under high vacuum. The residue was purified by column
- the silyl protected acetal 51 is a compound according to the first aspect of the invention, and corresponds to compound (Ic) (and compound (lb)) described above.
- v max filmVcm- 1 3336 (road), 2954, 1682, 1250 1098, 1044, 1006, 833, 778
- the t-butyl acetal 52 is a compound according to the first aspect of the invention, and corresponds to compound (Ic) (and compound (lb)) described above.
- Major diastereoisomer is a compound according to the first aspect of the invention, and corresponds to compound (Ic) (and compound (lb)) described above.
- the material was purified by column chromatography eluting with petrol/EtOAc (3: 1), to give the biphenyl acetal 53, (as an approximately 2:1 mixture of diasteroisomers, 236 mg, 54%) as pale yellow solids.
- the biphenyl acetal 53 is a compound according to the first aspect of the invention, and corresponds to compound (Ic) (and compound (lb)) described above.
- the lactone 54 is a compound according to the first aspect of the invention, and corresponds to compound (lb) described above.
- thiophene 550 mg, 524 ⁇ , 6.54 mmol, 1.1 eq.
- Anhydrous THF (26.5 ml) was added via syringe and the resulting solution cooled to -30 °C.
- 1.6 M n-BuLi (4.09 ml, 6.54 mmol, 1.1 eq.) was added dropwise and the solution stirred at -30 °C for 30 min.
- the solution was then cooled to -78 °C and CuCN (586 mg, 6.54 mmol, 1.1 eq.) added as a solid, in one portion.
- cuprate 25 corresponds to compound (IV) described above.
- Formed compound 26 corresponds to compound (V) described above.
- the alcohol 27 corresponds to compound (VI) described above.
- Alcohol 27 (300 mg, 0.75 mmol) was stirred with 1.5% aqueous HQ / THF (3:2) (15 ml) at r.t. for 16 h. The mixture was extracted with CH 2 CI 2 (5 x 25 ml) and the combined organic phases were dried (MgS0 4 ), filtered, and concentrated to give the triol 28 and silanol byproduct as a clear, colourless oil ( ⁇ 300 mg). This material was taken forward for the subsequent transformation without purification.
- the triol 28 corresponds to compound (VII) described above. 5F. (Z)-7-(lR,2R,3R,5S)-3,5-Dihydroxy-2-[(E,3S)-3-hydroxy-l- octenyl]cyclopentyl-5-heptenoic acid, PGF 2a (1)
- KOt-Bu (1.01 g, 9.03 mmol) was added in one portion and the resulting orange mixture stirred at 0 °C for 40 min.
- v max (neatVcm- 1 3339, 2961, 2930, 2857, 2490, 1705, 1457, 1380, 1245, 1118, 1086, 1047, 970, 910, 878, 731
- the aldol cascade used proline to perform the initial aldol reaction and a second catalyst ([Bn 2 NH 2 ][OCOCF 3 ]) to induce an intramolecular aldol reaction and elimination.
- the enantioselectivity was very high, isolation and purification was straightforward and the reaction could be conducted on multi-gram scale. Its application in a short synthesis of the most complex of prostaglandins, PGF 2a , has been demonstrated.
- bicyclic lactol 7 is an ideal building block not just for the cost-effective synthesis of the whole family of prostaglandins, but for also exploring chemical space around the ubiquitous five membered carbocyclic ring motif, where other biologically active molecules undoubtedly lie.
- Example 6 Experimental procedures for the synthesis of latanoprost
- the reaction was stirred at 0 °C for 1 h and then at r.t. for 23 h.
- the reaction mixture was concentrated under reduced pressure and purified by column chromatography ( ⁇ 200 g silica), eluting with petrol/EtOAc (9:1), to give the epoxide 3 as a dark red liquid.
- This was re- purified by column chromatography eluting with petrol/EtOAc (9.5:0.5 to 9:1), to give the epoxide 3 (4.62 g, 46%) as an orange liquid.
- the analytical data matched that of the racemic material described above.
- the enantioselectivity of the resolution was determined after subsequent conversion to the allylic alcohol 66.
- the optical rotation matched closely with that reported in the literature (Martynow, J. G. et al., European Journal of Organic Chemistry 2007, 2007, 689).
- Triphenylphosphine (695 mg, 2.65 mmol) and imidazole (222 mg, 3.26 mmol) were added as solids in one portion.
- Iodine (672 mg, 2.65 mmol) was added to the resulting solution. A slight exotherm was noted and the solution changed from a light yellow colour to a brown colour with the formation of a precipitate.
- the reaction was stirred at r.t. for 1 h.
- the reaction mixture was dry loaded onto silica (2 g) and purified by column chromatography (14 g silica), eluting with petrol to petrol/EtOAc (9: 1). This gave the iodide 69 (725 mg, 88%) as a clear, colourless oil.
- R f 0.20 (40/60 petroleum ether)
- thiophene (275 mg, 262 ⁇ , 3.27 mmol, 1.1 eq.) was added via syringe to a flame dried schlenk flask (evacuated and purged with nitrogen several times and allowed to cool).
- Anhydrous THF (13.3 ml) was added via syringe and the resulting solution cooled to -30 °C.
- 1.63 M n-BuLi (2.01 ml, 3.27 mmol, 1.1 eq.) was added dropwise and the solution stirred at -30 °C for 30 min.
- CuCN (293 mg, 3.27 mmol, 1.1 eq.) was added as a solid, in one portion.
- v max (neatycnrr 1 3434 (broad), 3026, 2928, 2856, 1496, 1471, 1454, 1360, 1343, 1254, 1098, 1053, 1004, 937, 833, 773, 698
- the reaction was quenched with H 2 0 (30 ml) and washed with Et 2 0 (2 x 30 ml) to remove triphenylphosphine oxide.
- the aqueous phase was made acidic with 1 M HQ ( ⁇ 10 ml) and extracted with CH 2 CI 2 (5 x 25 ml).
- the combined organic phases were dried (MgS0 4 ), filtered, and concentrated to give the crude material as solids. These were placed on a sinter funnel and washed with petrol/EtOAc (1: 1) (4 x 20 ml) and then EtOAc (2 x 40 ml).
- Zanoni and Vidari A modified procedure of Zanoni and Vidari was used (Zanoni, G. et al., Tetrahedron 2010, 66, 7472).
- Carboxylic acid 75 100 mg, 0.256 mmol was dissolved in DMF (2.0 ml) and stirred at r.t..
- Cs 2 C0 3 125 mg, 0.384 mmol was added in one portion followed by 2- iodopropane (51 ⁇ , 0.512 mmol). The reaction was stirred at r.t. for 18 h.
- the reaction mixture was poured into 3% citric acid solution (10 ml) and extracted with TBME (4 x 10 ml).
- v max (neatVcm "1 3360 (broad), 2980, 2931, 2857, 1712, 1495, 1454, 1374, 1311, 1247, 1180, 1106, 1030, 966, 910, 820, 731, 699
- bimatoprost (97) 7A. ( ⁇ )-5-Phenyl-l-(trimethylsilyl)pent-l-yn-3-ol, 81
- n-butyllithium (1.6 M in hexanes, 8.8 ml, 14.1 mmol, 1.0 eq.) was added dropwise to a solution of ethynyltrimethylsilane (2.0 ml, 14.1 mmol, 1.0 eq.) in THF (6 ml) at -78 °C. After addition, the mixture was allowed to warm slowly to 0 °C and stirred for 1 h.
- Tetrabutylammonium fluoride (1.0 M in THF, 25 ml, 25 mmol, 2.5 eq.) was added to a solution of (S)-5-phenyl-l-(tri/sopropylsilyl)pent-l-yn-3-ol 85 (3.165 g, 10 mmol, 1 eq.) in THF (95 ml). The reaction mixture was stirred for 1 h at r.t. and then quenched by addition of saturated aq. NH 4 CI (50 ml).
- the cooling bath was removed and the reaction mixture stirred at room temperature for 1 h.
- the reaction mixture was poured into water (100 ml) and extracted with 40/60 petroleum ether (4 x 50 ml).
- the combined organic phases were washed with water (100 ml), saturated Na 2 S 2 0 3 solution (2 x 100 ml) and brine (100 ml) before being dried (MgS0 4 ), filtered, and concentrated to give the crude material. This was purified by flash chromatography, eluting with 40/60 petroleum ether.
- thiophene (303 mg, 288 ⁇ , 3.6 mmol, 1.2 eq.) was added via syringe to a flame dried Schlenk flask (evacuated and purged with nitrogen several times and allowed to cool).
- Anhydrous THF (14.5 ml) was added via syringe and the resulting solution cooled to -30 °C.
- n-BuLi (1.6 M, 2.25 ml, 3.6 mmol, 1.2 eq.) was added dropwise and the solution stirred at -30 °C for 30 min. The solution was then cooled to -78 °C and CuCN (322.4 mg, 3.6 mmol, 1.2 eq.) added as a solid, in one portion.
- ⁇ ⁇ (mixture of 2 diastereoisomers, signals of minor diastereoisomer indicated by *) 0.05 (s, 3H, CH 3 ), 0.06* (s, 3H, CH 3 ), 0.07 (s, 3H, CH 3 ), 0.08* (s, 3H, CH 3 ), 0.93 (s, 9H, 3 x CH 3 ), 0.94* (s, 9H, 3 x CH 3 ), 1.74-2.52* (m, 8H, 3 x CH 2 , 2 x CH), 1.74-2.52 (m, 7H, 3 x CH 2 , CH), 2.56-2.76* (m, 2H, CH 2 ), 2.56-2.76 (m, 3H, CH 2 , CH), 3.35 (s, 3H, OCH 3 ), 3.39* (s, 3H, OCH 3 ), 3.81* (m, 1H, CHOH), 3.94 (m, 1H, CHOH), 4.15* (m, 1H, C/-OTBDMS), 4.
- N,N- Diisopropylethylamine (4.2 ml, 24 mmol, 1.6 eq.) and ethylamine (2 M solution in THF, 9.0 ml, 18 mmol, 1.2 eq.) were added dropwise.
- the reaction mixture was stirred for 1 h at 0 °C before being quenched by the addition of saturated aq. NH 4 CI (100 ml).
- the reaction mixture was extracted with Et 2 0 (4 x 75 ml) and the combined organic phases were washed with brine (100 ml) before being dried (MgS0 4 ), filtered, and concentrated to give the crude material.
- Triphenylphosphine (2.88 g, 11 mmol, 1.1 eq.) was added to a solution of 5-bromo-A/- ethylpentanamide 95 (2.08 g, 10 mmol, 1 eq.) in MeCN (5 ml) and the mixture was stirred for 14 h at 80 °C. The mixture was allowed to cool to r.t. and concentrated under vacuum. The residue was added dropwise into Et 2 0 (100 ml) and stirred vigourously for 10 min. The resulting solid was filtered, washed with Et 2 0 (2 x 10 ml) and dissolved in CH 2 CI 2 (15 ml).
- the process of the present invention surprisingly provides lactol (la) from succinaldehyde (II) with very high enantioselectivity while largely circumventing the other possible reaction pathways available.
- model aldehyde 16 was treated with proline.
- Aldol product 17 was obtained as a 3.6:1 mixture of diastereoisomers in moderate yield. This confirmed that aldol reactions of aldehydes bearing a carbonyl group in the 4-position were suitable substrates for the proline catalysed aldol reaction.
- model dialdehyde ( ⁇ )-18 was prepared by ozonolysis of known lactone ( ⁇ )-19. Treatment of this dialdehyde with proline provided only low conversion to the expected enal ( ⁇ )-20.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/407,367 US9242954B2 (en) | 2012-06-11 | 2013-06-11 | Lactol and acetal intermediates for making prostaglandins |
CA2914378A CA2914378C (en) | 2012-06-11 | 2013-06-11 | Prostaglandins, their intermediates and processes for their preparation |
JP2015515590A JP6392749B2 (en) | 2012-06-11 | 2013-06-11 | Compounds and methods |
EP13736609.2A EP2864308B1 (en) | 2012-06-11 | 2013-06-11 | (3aR,6aS)-2-Hydroxy-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde intermediates for the preparation of prostaglandins or prostaglandin analogues |
IL236154A IL236154A (en) | 2012-06-11 | 2014-12-09 | Compound, process for its manufacture and process for manufacturing a prostaglandin or a prostaglandin analogue using said compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1210235.6 | 2012-06-11 | ||
GBGB1210235.6A GB201210235D0 (en) | 2012-06-11 | 2012-06-11 | Compound and method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013186550A1 true WO2013186550A1 (en) | 2013-12-19 |
Family
ID=46605704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2013/051532 WO2013186550A1 (en) | 2012-06-11 | 2013-06-11 | Compound and method |
Country Status (7)
Country | Link |
---|---|
US (1) | US9242954B2 (en) |
EP (1) | EP2864308B1 (en) |
JP (1) | JP6392749B2 (en) |
CA (1) | CA2914378C (en) |
GB (1) | GB201210235D0 (en) |
IL (1) | IL236154A (en) |
WO (1) | WO2013186550A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160134741A (en) * | 2014-03-13 | 2016-11-23 | 키노인 기요기스제르 에스 베기에스제티 테르메크에크 기야라 제트알티. | New process for the preparation of high purity prostaglandins |
CN106810484A (en) * | 2016-12-28 | 2017-06-09 | 宁波第二激素厂 | The synthetic method of tromethamine dinoprost |
CN111018766A (en) * | 2018-10-10 | 2020-04-17 | 广州楷模生物科技有限公司 | Method for synthesizing bimatoprost |
CN113773185A (en) * | 2021-09-10 | 2021-12-10 | 万华化学集团股份有限公司 | Preparation method of 3, 6-dimethoxy-2, 7-dimethyl-4-octenedialdehyde |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011055377A1 (en) * | 2009-11-05 | 2011-05-12 | Biocon Limited | A novel process for the preparation of prostaglandins and intermediates thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3816462A (en) | 1970-11-27 | 1974-06-11 | Upjohn Co | Tricyclic lactone aldehyde |
GB1384646A (en) | 1972-05-10 | 1975-02-19 | Ici Ltd | Process for the preparation of prostaglandin intermediates |
US4213907A (en) | 1976-02-25 | 1980-07-22 | Pfizer Inc. | Prostaglandin intermediates |
WO1993023387A1 (en) | 1992-05-20 | 1993-11-25 | Japan Tobacco Inc. | Process for producing epoxide |
FR2725984B1 (en) | 1994-10-25 | 1997-01-10 | Pf Medicament | NOVEL AROMATIC ETHERS DERIVED FROM NAPHTYLPIPERAZINE USEFUL AS MEDICINES |
AU770343B2 (en) | 1999-09-06 | 2004-02-19 | Fumie Sato | Prostaglandin E analogues |
IL177762A0 (en) | 2006-08-29 | 2006-12-31 | Arieh Gutman | Bimatoprost crystalline form i |
-
2012
- 2012-06-11 GB GBGB1210235.6A patent/GB201210235D0/en not_active Ceased
-
2013
- 2013-06-11 EP EP13736609.2A patent/EP2864308B1/en not_active Not-in-force
- 2013-06-11 WO PCT/GB2013/051532 patent/WO2013186550A1/en active Application Filing
- 2013-06-11 JP JP2015515590A patent/JP6392749B2/en not_active Expired - Fee Related
- 2013-06-11 CA CA2914378A patent/CA2914378C/en not_active Expired - Fee Related
- 2013-06-11 US US14/407,367 patent/US9242954B2/en active Active
-
2014
- 2014-12-09 IL IL236154A patent/IL236154A/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011055377A1 (en) * | 2009-11-05 | 2011-05-12 | Biocon Limited | A novel process for the preparation of prostaglandins and intermediates thereof |
Non-Patent Citations (3)
Title |
---|
COULTHARD, GRAEME; ERB, WILLIAM; AGGARWAL, VARINDER K.: "Stereocontrolled organocatalytic synthesis of prostaglandin PGF2.alpha. in seven steps", NATURE, vol. 489, no. 7415, 15 August 2012 (2012-08-15), pages 278 - 281, XP002712012, DOI: 10.1038/nature11411 * |
ELIAS J. COREY, NED M. WEINSHENKER, THOMAS K. SCHAAF, WILLY HUBER: "Stereo-controlled synthesis of dl-prostaglandins F2.alpha. and E2", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 91, 1 September 1969 (1969-09-01), pages 5675 - 5677, XP002712010, DOI: 10.1021/ja01048a062 * |
SORENSEN, ERIK J.: "Organic synthesis:A biochemical messenger made easily", NATURE, vol. 489, no. 7415, 12 September 2012 (2012-09-12), pages 214 - 215, XP002712011, DOI: 10.1038/489214a * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160134741A (en) * | 2014-03-13 | 2016-11-23 | 키노인 기요기스제르 에스 베기에스제티 테르메크에크 기야라 제트알티. | New process for the preparation of high purity prostaglandins |
JP2017513816A (en) * | 2014-03-13 | 2017-06-01 | キノイン・ジヨージセル・エーシユ・ベジエーセテイ・テルメーケク・ジヤーラ・ゼー・エル・テー | New method for producing high-purity prostaglandins |
KR102422465B1 (en) * | 2014-03-13 | 2022-07-20 | 키노인 기요기스제르 에스 베기에스제티 테르메크에크 기야라 제트알티. | New process for the preparation of high purity prostaglandins |
CN106810484A (en) * | 2016-12-28 | 2017-06-09 | 宁波第二激素厂 | The synthetic method of tromethamine dinoprost |
CN106810484B (en) * | 2016-12-28 | 2019-04-12 | 宁波第二激素厂 | The synthetic method of tromethamine dinoprost |
CN111018766A (en) * | 2018-10-10 | 2020-04-17 | 广州楷模生物科技有限公司 | Method for synthesizing bimatoprost |
CN111018766B (en) * | 2018-10-10 | 2022-04-19 | 广州楷石医药有限公司 | Method for synthesizing bimatoprost |
CN113773185A (en) * | 2021-09-10 | 2021-12-10 | 万华化学集团股份有限公司 | Preparation method of 3, 6-dimethoxy-2, 7-dimethyl-4-octenedialdehyde |
CN113773185B (en) * | 2021-09-10 | 2022-08-05 | 万华化学集团股份有限公司 | Preparation method of 3, 6-dimethoxy-2, 7-dimethyl-4-octenedialdehyde |
Also Published As
Publication number | Publication date |
---|---|
US9242954B2 (en) | 2016-01-26 |
GB201210235D0 (en) | 2012-07-25 |
EP2864308B1 (en) | 2016-10-19 |
EP2864308A1 (en) | 2015-04-29 |
US20150158837A1 (en) | 2015-06-11 |
IL236154A (en) | 2017-03-30 |
CA2914378C (en) | 2021-01-05 |
IL236154A0 (en) | 2015-02-01 |
CA2914378A1 (en) | 2013-12-19 |
JP6392749B2 (en) | 2018-09-19 |
JP2015520181A (en) | 2015-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20020099034A1 (en) | Process for stereoselective synthesis of prostacyclin derivatives | |
EP2864308B1 (en) | (3aR,6aS)-2-Hydroxy-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde intermediates for the preparation of prostaglandins or prostaglandin analogues | |
US11691958B2 (en) | Enantioselective cross dehydrogenative coupling reactions and compounds synthesized by the reactions | |
JP2007538041A (en) | Method for producing diphenylazetidinone derivative | |
US7897793B2 (en) | Process for preparation of 13,14-dihydro-PGF2 alpha derivatives | |
Piers et al. | Intermolecular homocoupling of alkenyltrimethylstannane functions mediated by CuCl: Preparation of functionalized conjugated diene and tetraene systems | |
CN105254657B (en) | Metal catalytic asymmetry 1,4- conjugate addition reactions generate prostaglandin and prostaglandin analogue | |
CN110669046B (en) | Polysubstituted tetrahydro-gamma-carboline derivative with multiple chiral centers and preparation method of stereo diversity of polysubstituted tetrahydro-gamma-carboline derivative | |
TWI310763B (en) | Processes and intermediates for the preparations of prostaglandins | |
Loim et al. | Regio-and Enantioselective Synthesis of Planarly Chiral Cyclopentadienylmanganese Tricarbonyl Complexes via 2-Cymantrenyl-1, 3-dioxolanes | |
Fässler et al. | A Novel Stereoselective Reaction Cascade Leading from α‐Silylated Allylic Alcohols to Aldol‐Type Products | |
CN107001209B (en) | Formation of chromans based on intermolecular reactions of alkynes with dimethylfurans in the presence of gold (I) complexes | |
EP0494621B1 (en) | Substituted alkenoic acid and its derivatives | |
Jurys | Sulfenofunctionalization of double bonds with cyclic sulfenamides and anionic cascade cyclization reaction representing formal [2+ 2] enol-allene cycloaddition | |
US20150031898A1 (en) | Process for preparation of prostaglandin f2 alpha analogues | |
PL224738B1 (en) | Method for producing analogues of prostaglandin F2α structure 13,14-en-15-ol | |
Mathieson | A flexible one-step synthesis of dienamides: approaches towards a total synthesis of the Crocacins | |
WO2021070658A1 (en) | Method for producing cyclopentane compound, method for producing lactone compound, method for producing diol compound, and compound | |
JP2019513808A (en) | Preparation method of bimatoprost | |
Wang et al. | CHAPTER n. LACTONE FORMATION IN THE ADDITION OF BENZENESULFONYL BROMIDE TO DIENES AND ENYNE ESTERS | |
El-Awa | Asymmetric synthesis of dipropionate stereotetrads and application towards the total synthesis of Aplyronine A | |
Feuillet | Stereoselective synthesis of (e)-trisubstituted acid derivatives | |
Appeaning | Applications of titanium-mediated reductive coupling and cyclocarbonylation reactions toward natural product synthesis | |
EP2558439A1 (en) | A process for the preparation of isoserine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13736609 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015515590 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14407367 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2013736609 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013736609 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2914378 Country of ref document: CA |